6.015USD+2.47%Mkt Cap: 88.55M USDP/E: —Last update: 2026-05-26
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment o…
Industry Peers
Drug Manufacturers - Specialty & Generic152.45BSEKP/E 166.3
58.11BTRYP/E 27.8
55.80BEURP/E 22.1
33.63BPLNP/E 21.9
24.50BUSDP/E 21.3
18.90BUSD—
15.76BUSDP/E 24.1
13.30BEURP/E 30.3
Indicators:|
Key Statistics
Company
Market Cap88.55M USD
Enterprise Value81.29M USD
Revenue (TTM)41.94M USD
Gross Profit37.85M USD
Net Income (TTM)-2.84M USD
Revenue/Share2.823 USD
Last Price6.015 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees93
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)39.36
PEG1.67
EV/EBITDA-28.79
EV/Revenue1.94
P/S1.97
P/B3.82
EPS (TTM)-0.49
EPS (Forward)0.14
52W Range
1.85087% of range6.610
52W High6.610 USD
52W Low1.850 USD
Profitability
Gross Margin85.02%
Oper. Margin-34.27%
EBITDA Margin-6.73%
Profit Margin-6.37%
ROE-11.40%
ROA-3.69%
Growth
Revenue Growth-22.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF4.93M USD
CapEx (TTM)182.31K USD
FCF Margin11.70%
FCF Yield5.54%
Net Debt-937.46K USD
Net Debt/EBITDA0.33
Balance Sheet
Debt/Equity0.41
Current Ratio0.95
Quick Ratio0.73
Book Value/Sh1.444 USD
Cash/Share0.7350 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.14.98M
Float8.75M
Insiders41.60%
Institutions18.49%
Short Interest
Short Ratio0.2d
Short % Float5.98%
Short % Out.3.49%
Shares Short523.40K
Short (prev mo.)109.73K
Technical
SMA 503.746 (+60.6%)
SMA 2003.480 (+72.9%)
Beta-0.06
S&P 52W Chg28.31%
Avg Vol (30d)1.96M
Avg Vol (10d)141.87K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—